» Articles » PMID: 18085644

The Artificial Surface-induced Whole Blood Inflammatory Reaction Revealed by Increases in a Series of Chemokines and Growth Factors is Largely Complement Dependent

Overview
Date 2007 Dec 19
PMID 18085644
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Exposing blood to an artificial surface results in a systemic inflammatory response, including cytokine release and complement activation. We studied the artificial surface-induced inflammation in human whole blood using an extensive panel of inflammatory mediators including proinflammatory cytokines, chemokines and growth-factors and investigated the role of the complement system in the induction of this response. Using multiplex technology, 27 different inflammatory mediators were measured after circulating blood for 4 hours in polyvinyl chloride tubing. The C3 inhibitor compstatin was used to block complement activation. A significant (p < 0.05) increase in 14 of the 27 mediators was induced by the surface, of which 7 were chemokines (IL-8, MCP-1, MIP-1alpha, MIP-1beta, RANTES, eotaxin and IP-10) and 5 were growth-factors (G-CSF, GM-CSF, VEGF, PDGF and FGF). The traditional proinflammatory cytokines like IL-1beta, TNFalpha and IL-6 were not induced, although IL-6, as well as IL-15 and IL-17 increased if the surface was coated with highly bioincompatible laminaran. Inhibition of complement activation with compstatin significantly (p < 0.05) reduced the formation of 12 of the 14 mediators. For 10 of the 12 mediators, the inhibition was by 2/3 or more, for the remaining two the inhibition was more moderate. A highly biocompatible heparin-coated PVC surface was used as negative control and completely abolished the whole inflammatory response. The artificial surface PVC markedly induced a broad spectrum of chemokines and growth-factors, which was largely dependent on activation of complement.

Citing Articles

Effect of Intraperitoneal Radium-Labelled Microparticles on Compartmentalized Inflammation After Cytoreductive Surgery and Hypertherm Intraperitoneal Chemotherapy.

Thorgersen E, Asvall J, Schjalm C, McAdam K, Bruland O, Larsen S Technol Cancer Res Treat. 2023; 22:15330338231192902.

PMID: 37574949 PMC: 10426314. DOI: 10.1177/15330338231192902.


Depression among Patients with an Implanted Left Ventricular Assist Device: Uncovering Pathophysiological Mechanisms and Implications for Patient Care.

Alnsasra H, Khalil F, Perue R, Azab A Int J Mol Sci. 2023; 24(14).

PMID: 37511030 PMC: 10379142. DOI: 10.3390/ijms241411270.


Vascular Function in Continuous Flow LVADs: Implications for Clinical Practice.

Khalil F, Asleh R, Perue R, Weinstein J, Solomon A, Betesh-Abay B Biomedicines. 2023; 11(3).

PMID: 36979735 PMC: 10045906. DOI: 10.3390/biomedicines11030757.


MS-proteomics provides insight into the host responses towards alginate microspheres.

Coron A, Fonseca D, Sharma A, Slupphaug G, Strand B, Rokstad A Mater Today Bio. 2022; 17:100490.

PMID: 36420052 PMC: 9676213. DOI: 10.1016/j.mtbio.2022.100490.


Extensive adhesion formation in a total knee replacement in the setting of a gastrointestinal stromal tumor: A case report.

Mitchell S, Lee A, Stenquist R, Yatsonsky Ii D, Mooney M, Shendge V World J Orthop. 2022; 13(5):538-543.

PMID: 35633745 PMC: 9124998. DOI: 10.5312/wjo.v13.i5.538.


References
1.
Videm V, Mollnes T, Fosse E, Mohr B, Bergh K, Hagve T . Heparin-coated cardiopulmonary bypass equipment. I. Biocompatibility markers and development of complications in a high-risk population. J Thorac Cardiovasc Surg. 1999; 117(4):794-802. DOI: 10.1016/s0022-5223(99)70301-6. View

2.
Mollnes T, Lea T, Froland S, HARBOE M . Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol. 1985; 22(2):197-202. DOI: 10.1111/j.1365-3083.1985.tb01871.x. View

3.
Rinder C, Smith M, Rinder H, Cortright D, Brodbeck R, Krause J . Leukocyte effects of C5a-receptor blockade during simulated extracorporeal circulation. Ann Thorac Surg. 2006; 83(1):146-52. DOI: 10.1016/j.athoracsur.2006.08.019. View

4.
Andersson J, Sanchez J, Nilsson Ekdahl K, Elgue G, Nilsson B, Larsson R . Optimal heparin surface concentration and antithrombin binding capacity as evaluated with human non-anticoagulated blood in vitro. J Biomed Mater Res A. 2003; 67(2):458-66. DOI: 10.1002/jbm.a.10104. View

5.
Lappegard K, Riesenfeld J, Brekke O, Bergseth G, Lambris J, Mollnes T . Differential effect of heparin coating and complement inhibition on artificial surface-induced eicosanoid production. Ann Thorac Surg. 2005; 79(3):917-23. DOI: 10.1016/j.athoracsur.2004.08.015. View